Cytokinetics, Incorporated (CYTK)
NASDAQ: CYTK · IEX Real-Time Price · USD
68.00
-3.56 (-4.97%)
At close: Apr 15, 2024, 4:00 PM
69.00
+1.00 (1.47%)
After-hours: Apr 15, 2024, 7:42 PM EDT
Cytokinetics Stock Forecast
Stock Price Forecast
The 15 analysts with 12-month price forecasts for Cytokinetics stock have an average target of 80.53, with a low estimate of 50 and a high estimate of 108. The average target predicts an increase of 18.43% from the current stock price of 68.00.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Cytokinetics stock from 15 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 | 7 | 7 |
| Buy | 6 | 7 | 6 | 6 | 6 | 6 |
| Hold | 2 | 2 | 4 | 3 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15 | 16 | 17 | 16 | 15 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $108 | Strong Buy | Reiterates | $108 | +58.82% | Apr 9, 2024 |
| Truist Securities | Truist Securities | Strong Buy Reiterates $86 | Strong Buy | Reiterates | $86 | +26.47% | Apr 8, 2024 |
| JP Morgan | JP Morgan | Buy Maintains $78 → $77 | Buy | Maintains | $78 → $77 | +13.24% | Mar 7, 2024 |
| Mizuho | Mizuho | Strong Buy Maintains $103 → $99 | Strong Buy | Maintains | $103 → $99 | +45.59% | Mar 6, 2024 |
| Oppenheimer | Oppenheimer | Buy Reiterates $107 | Buy | Reiterates | $107 | +57.35% | Mar 4, 2024 |
Financial Forecast
Revenue This Year
6.54M
from 7.53M
Decreased by -13.21%
Revenue Next Year
148.22M
from 6.54M
Increased by 2,168.09%
EPS This Year
-4.54
from -5.45
EPS Next Year
-3.37
from -4.54
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 47.7M | 414.4M | 707.9M | 1.4B | 1.9B |
| Avg | 6.5M | 148.2M | 530.4M | 939.4M | 1.4B |
| Low | n/a | 4.9M | 304.5M | 547.7M | 927.0M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 533.5% | 6,241.1% | 377.6% | 156.2% | 102.6% |
| Avg | -13.2% | 2,168.1% | 257.9% | 77.1% | 52.5% |
| Low | - | -25.0% | 105.4% | 3.3% | -1.3% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -3.60 | -1.61 | 1.09 | 2.02 | 5.23 |
| Avg | -4.54 | -3.37 | -0.89 | 0.90 | 3.31 |
| Low | -5.39 | -5.13 | -2.13 | -1.57 | 1.74 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | 479.3% |
| Avg | - | - | - | - | 266.4% |
| Low | - | - | - | - | 93.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.